HQ Function

Served as the company's main corporate office and primary research and development center, housing laboratories for drug discovery and early clinical development programs in neurodegenerative diseases.

Notable Features:

The facility was situated within Boston Landing, a modern mixed-use development known for attracting life science and technology companies. It offered advanced laboratory facilities suitable for biopharmaceutical research. This facility and some personnel were acquired by Kineta, Inc. as part of the reverse merger.

Work Culture:

As a mission-driven biopharmaceutical company, Yumanity Therapeutics likely fostered an innovative, scientifically rigorous, and collaborative work environment. The culture would have been characterized by a strong focus on research excellence and a shared goal of developing treatments for debilitating neurodegenerative diseases.

HQ Significance:

The Boston/Cambridge biotech ecosystem provided Yumanity with access to world-class scientific talent, leading academic and medical institutions, specialized service providers, and a strong investor community, crucial for its R&D efforts.

Values Reflected in HQ: The choice of a modern R&D facility in a major biotech hub reflected Yumanity's commitment to cutting-edge science, innovation, and collaboration in its pursuit of novel therapies.

Location:

Yumanity Therapeutics' operations were primarily centered in the United States, with its headquarters and main research facilities located in Boston, Massachusetts. While its physical office presence was concentrated in the U.S., its scientific collaborations, clinical trial activities for its drug candidates, and investor relations may have extended internationally, which is common for biopharmaceutical companies addressing diseases with a global impact.

Street Address:

40 Guest Street, Suite 4410

City:

Boston

State/Province:

MA

Country:

USA